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Abstract: On a global basis, both potent vaccine efficacy
and high vaccine coverage are necessary to control and
eliminate vaccine-preventable diseases. Emerging evi-
dence from animal and human studies suggest that
neglected tropical diseases (NTDs) significantly impair
response to standard childhood immunizations. A review
of efficacy and effectiveness studies of vaccination among
individuals with chronic parasitic infections was conduct-
ed, using PUBMED database searches and analysis of data
from the authors’ published and unpublished studies.
Both animal models and human studies suggest that
chronic trematode, nematode, and protozoan infections
can result in decreased vaccine efficacy. Among pregnant
women, who in developing countries are often infected
with multiple parasites, soluble parasite antigens have
been shown to cross the placenta and prime or tolerize
fetal immune responses. As a result, antenatal infections
can have a significant impact on later vaccine responses.
Acquired childhood parasitic infections, most commonly
malaria, can also affect subsequent immune response to
vaccination. Additional data suggest that antiparasite
therapy can improve the effectiveness of several human
vaccines. Emerging evidence demonstrates that both
antenatal and childhood parasitic infections alter levels
of protective immune response to routine vaccinations.
Successful antiparasite treatment may prevent immuno-
modulation caused by parasitic antigens during pregnan-
cy and early childhood and may improve vaccine efficacy.
Future research should highlight the varied effects that
different parasites (alone and in combination) can have on
human vaccine-related immunity. To optimize vaccine
effectiveness in developing countries, better control of
chronic NTDs may prove imperative.
Introduction
Since the inception of the Expanded Program on Immunization
(EPI) in 1974, many global partners, including the World Health
Organization, United Nations Children’s Fund, and the Gates
Foundation, have joined to support mass global immunization
projects that have resulted in a significant drop in child mortality
worldwide [1]. Programmatic effectiveness has been primarily
measured as the operational improvement in vaccine coverage,
with the tacit assumption that average individual vaccine response
(i.e., average vaccine efficacy) remains the same for all populations
[2,3]. For example, the Global Alliance for Vaccines has improved
the percentage of children receiving diphtheria–tetanus–pertussis
(DTP) vaccinations from 71% in 1999 to 78% in 2004 [4]. Despite
these impressive attempts at mass vaccination coverage, vaccine-
preventable diseases still kill an estimated 1 to 2 million African
children each year [5]. Whereas efficacy is the measure of the
impact of treatment in an ideal (study) environment, effectiveness
is the measure of impact in ‘‘real-world’’ settings [6]. These
preventable deaths contribute to the high infant and childhood
mortality rates experienced by these countries and, by definition,
highlight the lapse in vaccine effectiveness in resource-poor areas.
Vaccines are among the most cost-effective health interventions
available for the prevention of life-threatening and disabling
infectious diseases. Even so, the overall effectiveness of vaccine
strategies requires both adequate coverage among vulnerable
populations and induction of a satisfactory protective immune
response in each susceptible individual. Although extensive
resources are now being committed to improve global childhood
vaccination coverage, in developing nations the response to
standard vaccination often remains suboptimal [2,7–12]. The
reasons for this poor vaccination response are undoubtedly
complex, yet there are several causes that are likely to be
amenable to intervention or preventive treatment (Figure 1). In
particular, emerging clinical evidence suggests that chronic
antenatal parasitic infection can significantly alter infant immune
responses to standard childhood vaccinations [13–21]. More
limited evidence also suggests that parasitic infections in the first
few years of life can also impact immunity and response to
vaccines [22]. In this review, our premise is that vaccine
effectiveness will not be optimal among children of developing
countries until there is adequate treatment and prevention of
antenatal and early childhood parasitic infections.
The reduced effectiveness of vaccination programs in develop-
ing communities often has been blamed on cold-chain lapses and a
lack of support infrastructure [23–27]. However, as detailed later
in this review, chronic infections with neglected tropical diseases
(NTDs) also appear to play a significant role in poor vaccine
efficacy. Of special interest, maternal parasitic infections affect the
unborn infant and appear to act as important immune response
modifiers, although the mechanisms of the parasite-induced
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suggests that maternal parasitic infections such as schistosomiasis
[28], filariasis [28–30], other helminths [31], and malaria [32]
during the period of gestation can suppress an infant’s later
immune responses to standard childhood vaccinations.
Population-Based Evidence of Reduced Vaccine
Effectiveness
Several vaccination studies have shown that children from areas
of sub-Saharan Africa are less responsive to standard childhood
vaccines than children from developed countries. These include
vaccine trials of the antituberculosis vaccine BCG (Bacillus
Calmette-Guerin) [7,8,33] and of typhoid fever [9], measles
[10,23], and polio vaccines [11,12]. For example, after receiving
three oral polio vaccines, vaccinated children from industrialized
nations have 97%, 100%, and 100% seroconversion rates to polio
virus types 1, 2, and 3, whereas vaccinated children from developing
nationsshowonly 73%,90%,and 70%protection, respectively[11].
What are the implications of this phenomenon? Recent
outbreaks of polio in Africa show us that our ‘‘control’’ of
vaccine-preventable diseases is tenuous at best. A short-term
failure in vaccine coverage resulted in the rapid and serious
resurgence of a vaccine-preventable disease [34]. In recent
Nigerian polio outbreaks, the rapid spread to nearby African
countries was in part related to low herd immunity caused by
decreased vaccine coverage (10 countries) [35]. Of special
importance, however, polio also reemerged in well-vaccinated
African countries such as Ghana, Botswana, and, now more
recently, Kenya, where the vaccine coverage rate was high
(.90%) [35,36]. Vaccine programs in these countries were
ineffective in preventing these outbreaks, despite high vaccination
coverage, suggesting suboptimal vaccine efficacy among at-risk
individuals within well-vaccinated local populations.
Potential Causes of Reduced Efficacy in
Developing Countries
Failure to respond appropriately to vaccination is most often
associated with a suite of poverty-related conditions, including both
malnutrition and chronic infection. Clinical features of poverty
include protein-calorie and micronutrient undernutrition and
recurring exposure to parasites (protozoa and helminths) that
independently contribute to chronic anemia and poor physical
growth and development [37]. Chronic parasitic infections also have
a substantial impact on cognitive and intellectual development and
education[38–40].Fortunately,manyofthesedeleteriouseffectscan
be reversed with antiparasite treatment [41–44]. However, reinfec-
tion remains common in this setting, and the global burden of
parasitic infections remains unacceptably high [45].
Effects of Parasitic Infection on Host Immunity
The deleterious effects of polyparasitism on host immunity may
help to explain the poor response to childhood vaccination that is
seen in the developing world. Both animal and human studies
indicate that parasitic infections can impair long-term responses to
vaccination. In addition, multiple concurrent infections are likely to
have additive or synergistic effects on immune responses. Studies in
both human and animal models have shown that trematode,
nematode, and Plasmodium infections lead to decreased vaccine
efficacy and an inability to ward off new infection [19,46–48].
Trematode Infections
Elias et al. [15] compared the efficacy of BCG vaccine in mice
with and without Schistosoma mansoni infection and determined that
BCG-vaccinated, schistosome-infected mice have significantly less
vaccine-induced protection against virulent tuberculosis challenge
than those without schistosome infection. In studies of humans
with trematode infection, a decreased response to tetanus toxoid
vaccination has been demonstrated in the presence of schistoso-
miasis, associated with significantly altered Th1- and Th2-type
immune responses to tetanus toxoid in vitro [18].
Nematode Infections
Two studies performed in mice show that nematode infection
impairs response to malaria vaccination and further illustrate that
cure of parasitic infection before immunization, and not after,
increases host vaccine response [18,46,47]. Additionally, in
humans, deworming with albendazole has been shown to improve
the effectiveness of vaccine response to BCG [16] and to oral
cholera vaccine [13,14].
Protozoan Infections
Chronic protozoan infections also have been proven to have
harmful effects on vaccination response, with decreased levels of
response to tetanus, Haemophilus influenzae type b [5], and typhoid
vaccines noted in the presence of concurrent malaria infection
Figure 1. Theoretical mechanisms of reduced vaccine response in infants.
doi:10.1371/journal.pntd.0000442.g001
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vaccine response is controversial and appears to depend on which
vaccines are tested. No effect was observed on DTP and measles
vaccination [49,50], but malaria treatment has been found to be
associated with improved immunization response to meningococ-
cal vaccines [51,52].
Evidence on the Impact of Antenatal Parasite
Infection on Later Childhood Vaccine Responses
‘‘Imprinting’’ of the immune system during fetal development also
may play a significant role in reduced vaccine effectiveness in
parasite-endemic areas. In developing countries, women of child-
bearing age are frequently infected with one or more parasites, as
seen in our cohorts in coastal Kenya and others [53] (Figure 2). If left
untreated, their chronic infections will persist throughout the period
of pregnancy. As a consequence of persistent infection, soluble
parasite-derived products cross the placenta, potentially priming or
tolerizing the fetal immune system’s response to theseparasite-specific
antigens and to unrelated antigens [31]. Many helminth-mediated
immunoregulatory effects drive the balance of human host immunity
towards Th2-type reactivity, yet natural or vaccine-mediated
immunity requires mainly Th1-type responses to provide vaccine-
mediated protection [30,54]. On the basis of emerging evidence from
longitudinal maternal–infant cohort studies, exposure to parasites in
utero appears to induce an immunomodulatory phenotype that
persists into infancy and later childhood, significantly affecting
protective responses to antigens included in standard childhood
vaccines (Figure 3). The treatment of helminthic infections during
pregnancy has been shown to have many beneficial effects, including
the reduction of HIV mother-to-child transmission (MTCT), low
birth weight incidence, and infant mortality [55]. Data suggest many
other detrimental effects of chronic maternal parasitic infection on
infant outcomes [55–64]. Whether or not parasitic treatment of
pregnant women can impact infant immunization efficacy has not
been adequately studied, although evidencesuggests that treatment of
parasitic infections in pregnant women has significant immunity-
modifying effects in their infants [28,65].
Evidence on the Impact of Early Childhood
Parasitic Infection on Vaccination Responses
Successful treatment of pregnant mothers for parasitic infections
may prevent sensitization to parasitic antigens during pregnancy
and may improve vaccination outcomes of the unborn child by
diminishing parasite-driven fetal priming. Later primary exposure
to parasitic infections during the first years of life also can affect
subsequent immune response to vaccination. Although malaria is
the most common parasitic infection in young children, schisto-
somiasis, filariasis, and intestinal helminthic infections also have
been shown to occur in infants [30,66,67]. Polyparasitism is known
to affect immune function and vaccination response
[15,18,19,46,47]. The evidence that early childhood parasitic
treatment yields improved response to vaccination is sparse and
deserves further study [16,51,52].
Figure 2. Typical profile of parasitic infection prevalence among pregnant women attending an antenatal clinic in coastal Kenya.
Dual infection was detected in 26% of women; three or more infections were detected in 11% of women.
doi:10.1371/journal.pntd.0000442.g002
Figure 3. Effect of maternal helminth infection on an infant’s
acquisition of protective antibodies (polyribosylribitol phos-
phate-specific IgG) following Haemophilus influenzae type b
vaccination at 6, 10, and 14 wk of age. Values represent geometric
means (695% confidence interval) for infants subsequently tested at 6
months of age. *p,0.001 for observed differences between the
offspring of uninfected versus multiply parasitized women.
doi:10.1371/journal.pntd.0000442.g003
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Studies have clearly established the presence of T and B cell
responses by the human fetus to maternal parasitic infections
[32,68–70]. Animal models suggest that exposure to parasites in
utero may be either beneficial (by accelerating the development of
protective antibodies and cellular immune responses) or detri-
mental (by impairing the acquisition of a protective immune
response and inducing immune tolerance) [71–74].
Immune tolerance may be due to clonal deletion of specific cell
subsets, which leads to loss of antigen-reactive cells in utero and
subsequent lack of recall response during antigen exposure later in
infancy. Another possible tolerance mechanism is clonal anergy,
which results from a lack of adequate costimulation by antigen-
presenting cells to CD4+ cells. Finally, tolerance may be due to the
de novo generation of populations of immunoregulatory cells.
Prenatal exposure to malaria, schistosomiasis, and filariasis may
lead to the acquisition of a subset of immunoregulatory CD4+ T
cells. A distinct population of CD4+ regulatory-1 cells (Tr1) has
been shown to be able to arise from CD34+ cells in the neonate
[75] in response to IL-10 and IFN-a [76]. Specifically, IL-10 has
been proposed to be responsible for modulating subsequent
immune responses during subsequent exposure to new, unrelated
antigens. Tr1 cells are antigen-specific CD4+ cells that are distinct
from Th1 and Th2 cells in that they produce significant amounts
of IL-10, variable IFN-c, TGF-b, and IL-5, but little or no IL-2
and no IL-4. The CD4+CD25+ T cells represent another
population of regulatory T cells whose development is partially
mediated by IL-10 and TGF-b [77]. As with chronic helminth
infections, exposure to maternal malaria leads to the generation of
significant levels of malaria blood stage antigen-driven IL-10 in
cord blood and infant lymphocytes. Presumably, this immuno-
modulation may benefit the human host by limiting inflammation
caused by chronic parasite infections in early childhood and later
adolescence. However, the concomitant downside is a reduced
ability to respond to acute bacterial and viral infections and to
vaccination.
In humans, ‘‘tolerance’’ (manifested by the generation of
immunoregulatory populations of lymphocytes by prenatal
antigenic exposure) is likely to contribute to the long-term
persistence of many intravascular parasitic infections [30,54,78–
80]. In our studies, tolerance is defined as an altered or suppressed
immune response to parasite antigens during infancy or childhood
in the progeny of women infected during pregnancy. Maternal
infection with lymphatic filariasis, schistosomiasis, and the
protozoan parasites Trypanosoma cruzi and T. gondii have been
shown to enhance the offspring’s susceptibility to subsequent
infection, and this phenomenon is associated with impaired or
altered fetal immune response to parasite antigens. Children born
to filarial-infected mothers, for example, have depressed cytokine
responses in T cells and lymphocyte proliferation by peripheral
blood mononuclear cells to filarial antigens compared to offspring
from uninfected mothers. They are also significantly more likely to
acquire filarial infection in the first 5 years of life and continue to
show altered responses to parasite antigens years after birth [29].
Not all in utero exposure to maternal helminth infections results
in tolerance. Instead, for some newborns, prenatal parasite
exposure results in a constant state of antiparasite immune
activation that is characterized by a Th2-dominant cytokine
profile, high IgE levels, and eosinophilia. Such an immune profile
also may have an adverse impact on the efficacy of vaccines by
limiting Th1 pathways of immune response to vaccination. By
altering the immunologic balance between Th1 and Th2
pathways, chronic parasitic infections appear to alter the
immunologic milieu and would also likely impair or suppress the
‘‘normal’’ responses to vaccines that have been described in
parasite-free, developed countries.
Other Implications of Parasite Infection for
Infectious Disease Transmission
Polyparasitism’s effects on immunity are believed to be partly
responsible for the increasing virulence of the world’s most lethal
infections: HIV [81,82], malaria [83,84], and tuberculosis [85,86].
In addition, helminth infection is associated with an increased risk
for MTCT of HIV [87]. Some studies of HIV–parasite coinfection
suggest that antihelminthic therapy may reduce CD4 depletion
and progression of viral load in HIV-infected patients [88].
Parasite effects on immunity need to be highlighted as new
vaccines against HIV, malaria, and tuberculosis are moving
forward in clinical trials, because optimal vaccine efficacy may
require effective antiparasite therapy to control for the immune
system impact of these chronic pathogens [38,89–92].
Suggestions for Current Antenatal and Infant
Care and for Future Research
A growing body of evidence now demonstrates that antenatal
and childhood parasitic infections both deleteriously alter
responses to routine vaccination. To truly optimize vaccination
campaign effectiveness and vaccine efficacy in all areas of the
world, parallel efforts are needed to control endemic parasitic
infections. More data are needed to identify the multifactorial
causes of impaired vaccine efficacy, including research specifically
addressing the impact of preventive antiparasite therapy on
maternal and infant health outcomes.
The immune response to parasites can be beneficial or
detrimental. Immune modulation makes it difficult to predict the
impact of intermittent parasite treatment. Perhaps a repeating
cycle of infection/treatment/reinfection may be worse for vaccine
response than low level chronic infection. This area is worthy of
further study and must determine the appropriate treatment
intervals for these infections. Also, more data are needed to
objectively define the optimal timing between deworming and
vaccination. Ideally, pregnant women should be free of infection
throughout all three trimesters of pregnancy, but perhaps
reinfection in the last trimester is particularly detrimental with
respect to fetal priming. Ultimately, a carefully designed double-
blind, placebo-controlled trial in infected pregnant women would
provide the critical evidence to support or refute the need for
antenatal parasitic treatment.
If antenatal and early child deworming are to be implemented
as standard interventions, then the associated changes in vaccine
efficacy and effectiveness should be concurrently documented in
well-designed, prospective studies. Animal models suggest that the
loss of cross-protective or immunomodulatory effects of polypar-
asitism may mean that some parasitic diseases may become
clinically worse before they are fully eradicated. So far, the
available evidence indicates that deworming has clear benefits in
terms of birth outcomes [62,93]. If deworming is also found to
amplify vaccination effects, then it is clearly time to intensively test
and implement antiworm strategies and their ‘‘indirect vaccina-
tion’’ effect on at-risk populations. Ultimately, because of the real-
world roadblock that parasite infections present to vaccine
effectiveness, mass vaccination campaigns likely will not reach
their full potential unless vaccines and antiparasite strategies are
implemented together.
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